SALT LAKE CITY, UT -- (Marketwire) -- 10/07/08 -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com), announced today that it has acquired the exclusive North American license to specific application of novel proprietary technology used to perform pharmacokinetic analysis of therapeutic drugs in patients, from Saladax Biomedical, Inc. The technology allows a physician to adjust a patient's dose of chemotherapy to provide optimal patient exposure to the chemotherapy to help improve efficacy and minimize toxicity during the course of treatment.

Therapeutic drug management has long been used in infectious disease, transplantation and neurological disease treatment to improve the effectiveness and safety of drugs. Advances in personalized medicine have now made possible expansion of the same principle to the treatment of cancer patients, so that they can benefit from a reduction in toxicity and an increase the efficacy of the chemotherapy.

"We are very pleased to be working with Saladax in the commercialization of this exciting technology," said Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc. "This pioneering effort will not only benefit patients, but will complement our current product portfolio and will be readily sold through our existing 150-person oncology salesforce."

Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of novel therapeutic and molecular diagnostic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

Saladax Biomedical is pioneering the development of novel Personalized Chemotherapy Management(TM) (PCM) immunoassays that enable routine blood-level monitoring of anti-cancer drugs. More information about Saladax and PCM is available at www.saladax.com

PCM is a trademark of Saladax Biomedical, Inc. in the United States.

MYGN-G

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the ability of the technology to allow a physician to adjust a patient's dose of chemotherapy to provide optimal patient exposure to the chemotherapy to help improve efficacy and minimize toxicity during the course of treatment; and the extent to which our efforts will benefit patients and will complement our current product portfolio and will be readily sold through our existing 150-person oncology salesforce.